Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions - Wikidata - awgldk - TriplyDB

Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

http://www.wikidata.org/entity/Q35971694

about

VEGF inhibition and renal thrombotic microangiopathy Fluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculature Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism Antiangiogenic treatment diminishes renal injury and dysfunction via regulation of local AKT in early experimental diabetes Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease.Alteration of podocyte protein expression and localization in the early stage of various hemodynamic conditions Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism Effects of restoring normoglycemia in type 1 diabetes on inflammatory profile and renal extracellular matrix structure after simultaneous pancreas and kidney transplantation Folic acid mitigates angiotensin-II-induced blood pressure and renal remodeling.SDF-1/CXCR4 signaling preserves microvascular integrity and renal function in chronic kidney disease.Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Hyperglycemia and renal mass ablation synergistically augment albuminuria in the diabetic subtotally nephrectomized rat: implications for modeling diabetic nephropathy Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes.Repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial.eNOS deficiency predisposes podocytes to injury in diabetes.The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes.Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.Expression, localization, and function of the thioredoxin system in diabetic nephropathy.Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.Abnormal angiogenesis in diabetic nephropathy.Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes.Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?The conflicting effects of maternal nutrient restriction and early-life obesity on renal health.What are new avenues for renal protection, in addition to RAAS inhibition?The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms.The endothelium in diabetic nephropathy.Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.Impaired Neovascularization and Reduced Capillary Supply in the Malignant vs. Non-malignant Course of Experimental Renovascular Hypertension CLIC5A, a component of the ezrin-podocalyxin complex in glomeruli, is a determinant of podocyte integrity Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.SIRT1 activation ameliorates hyperglycaemia by inducing a torpor-like state in an obese mouse model of type 2 diabetes.Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis.Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD.Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors?Gene polymorphism of vascular endothelial growth factor -1154 G>A is associated with hypertensive nephropathy in a Hispanic population.

P2860

Q24632792-0BFCEB54-1A7A-49C6-8713-FEEEB8F2BCC3 Q27320632-3C1FFCC2-9473-4316-B350-623C0C3E1AC9 Q27333630-F1CF2279-ED4C-44F6-BF29-BB0F670A1DF9 Q28538183-A2946157-8D60-47FE-947B-AF4189E7EA92 Q33552200-71D57F0B-5B0B-44CE-8E2A-FF30BDC993E7 Q33794256-712F271C-B55C-4A22-8ED1-EA6C7B6AC91C Q34624417-613CBA8D-2BA8-4C0B-BD5A-7D51CAB6F174 Q34839640-1ED5DA32-4819-4F66-BFB9-7213BF93EF7C Q35073484-EEFB4878-C8FB-4558-A00C-118CD080CA11 Q35080666-1D09BFF2-AC02-4A35-9337-2ACFD9F07F24 Q35123087-4A8F3218-7F28-4A7D-AFC4-C83E63507FF3 Q35217148-1CDBE0F1-7B22-442C-967A-4B9B4827EBC2 Q35887931-DB8AFB04-F351-4096-8EB9-05128EED5ECE Q36058792-D7E67FC0-414E-4DFD-9CFB-CB6A358CC30F Q36109260-32109FBC-8B6C-40EE-BBB7-F932362A3AB9 Q36278420-D7BD3E88-6676-4B87-ACFC-7CA7B6850D74 Q36352132-0CDFF0B4-D00F-42BD-8E5C-F0924BD35C4F Q37051959-9B3F2AF4-C436-4C6A-9729-85CBF25005E1 Q37142636-3EF491E4-916E-4C34-AB1C-8ED4997822D8 Q37146420-A6D3F444-E363-4BD7-855E-80CBE5242460 Q37154812-780AC5BE-3E72-48C4-B7DC-BBCA6B9765A1 Q37236268-F9F7EF35-D5BB-43B8-864D-46BE723D416E Q37251105-C72BF10E-C620-40C7-93EC-2B140451F300 Q37329315-E0187174-5F82-4268-B235-827DB3CF79A3 Q37353319-2B35AE42-9911-4894-B4E9-E1E7D6246FCB Q37688711-B8E1E003-99F9-453F-8A41-60960966E021 Q37828185-3C3BA1F4-4EE5-408A-954C-3AE2B1BA505A Q37980677-80BD70AF-471D-4441-9976-E95B410BFE73 Q38014802-04A9D252-58A8-4427-B368-22BC3922BF9A Q38195528-46A468BF-5E2F-482F-919D-17B3B70A09C0 Q39780036-586EE6D3-9AE8-4A96-A009-721C9509D105 Q40969480-F625324B-830C-43E7-B238-65C774175907 Q41011996-0041C66F-2478-4117-8B76-10B2F0985A64 Q41822455-91C859FC-9486-44F0-9C86-B84368E3F7B1 Q41827523-FB16BCBC-9F16-4683-98A6-FFC35F864F84 Q42181142-57C9AD62-E5B8-44B4-8C96-829E4E19ACC8 Q42292968-3C3AC402-8A55-4AC5-A73B-68174767E133 Q42499130-F70ABBB5-92F3-4998-90BF-5348C8AD8627 Q42543049-87E06E0A-1316-4D59-AB31-48203B52EA83 Q44562858-EB9CB449-D3AD-4BFC-8B9A-8B3EA1BE49AD

P2860

Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

http://www.wikidata.org/entity/Q35971694

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Role of VEGF in maintaining re ...... ve and hypertensive conditions

@ast

Role of VEGF in maintaining re ...... ve and hypertensive conditions

@en

type

label

Role of VEGF in maintaining re ...... ve and hypertensive conditions

@ast

Role of VEGF in maintaining re ...... ve and hypertensive conditions

@en

prefLabel

Role of VEGF in maintaining re ...... ve and hypertensive conditions

@ast

Role of VEGF in maintaining re ...... ve and hypertensive conditions

@en

P1433

Q35971694-9C57D40E-889E-4BF2-9EB9-634C03F48A7F

P1476

Q35971694-1F241936-D818-4400-97DC-87E5832EFF27

P2093

Q35971694-067EAF31-0DF6-4167-BB28-A7AE0EED2C42

Q35971694-088DCC87-9FFC-49A9-82C5-3FFE8C177E44

Q35971694-0BB3834A-A34F-44C6-A47F-3AAF40B97AD7

Q35971694-28036A50-F5FF-4915-B1E8-45E82A99C073

Q35971694-364EB996-F312-4C0E-A842-84276F37EC8A

Q35971694-3BCD7448-ABCD-4265-820A-FE9568364B44

Q35971694-47841F23-F4FB-4C3B-B1A6-C5EE3335BF06

Q35971694-94F99FEF-6F5E-4432-80E1-60D8B4CF3C54

Q35971694-B3982DFD-2AA3-4851-A42C-AA56156DB5DC

Q35971694-C1EF11BE-4986-4CAA-8BC6-79BEEA8279B8

P2860

Q35971694-08281C6B-735D-430A-916F-88CA834A29EE

Q35971694-0B616955-1018-4DEC-9E6C-336398600811

Q35971694-0E4F347F-C982-4413-9ECE-3FE024FA9E9F

Q35971694-10C5ED32-4010-4B22-BDF6-647F68616AD8

Q35971694-135ED587-A63F-4514-8772-D9E487B9D509

Q35971694-1BD5D9A2-0F51-4736-817E-9848F14B5FC6

Q35971694-21385A27-7214-45D0-BE0A-DA0AA47AB218

Q35971694-214F656F-E374-4161-8DFA-C618FA49914F

Q35971694-2EF60F14-068F-44CB-AB46-4C036BDC0773

Q35971694-348A70CA-D7DE-45C2-8FDC-5EE8D5E0BEB6

P304

Q35971694-845A1B3D-D169-4A25-B803-7AD9AA43F26D

P31

Q35971694-984DC354-07EC-4384-81F3-6804E351D213

P356

Q35971694-360A5417-4E7B-4872-B043-BE45D9AA87CD

P407

Q35971694-5274B7BC-3BC5-4BE7-B004-F16A499CBD22

P433

Q35971694-B58987E1-25D1-4726-A1AF-0629529AC6C7

P478

Q35971694-A4640B34-27B5-4A26-B6ED-49CE886BD4E1

P50

Q35971694-B460A9D0-DDC4-4C14-8829-DC8673DFF0FE

P577

Q35971694-2207B5D6-3E58-4A1F-9435-82B63701F460

P5875

Q35971694-A90D20E5-6C98-4DE9-A330-879AAB4C77FF

P698

Q35971694-EFC0B1EB-94F5-47C5-8C8F-9B4712E9A8B1

P932

Q35971694-B6825288-29EC-4934-950D-77ECC62B1BF7

P356

PNAS.0703577104

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Role of VEGF in maintaining re ...... ve and hypertensive conditions

@en

P2093

Alison J Cox

http://www.w3.org/2001/XMLSchema#string

Andrew Advani

http://www.w3.org/2001/XMLSchema#string

Brent M Steer

http://www.w3.org/2001/XMLSchema#string

Kathryn E White

http://www.w3.org/2001/XMLSchema#string

Kerri Thai

http://www.w3.org/2001/XMLSchema#string

P Elizabeth Rakoczy

http://www.w3.org/2001/XMLSchema#string

Philip A Marsden

http://www.w3.org/2001/XMLSchema#string

Renae M Gow

http://www.w3.org/2001/XMLSchema#string

Richard E Gilbert

http://www.w3.org/2001/XMLSchema#string

Sally M Marshall

http://www.w3.org/2001/XMLSchema#string

P2860

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1

Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue.

Amelioration of diabetic peripheral neuropathy by implantation of hematopoietic mononuclear cells in streptozotocin-induced diabetic rats.

Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy.

Malignant hypertension - the role of the paracrine renin-angiotensin system.

P304

14448-14453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0703577104

http://www.w3.org/2001/XMLSchema#string

P407

P433

36

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6114468

http://www.w3.org/2001/XMLSchema#string

P698

17726104

http://www.w3.org/2001/XMLSchema#string

P932

1964850

http://www.w3.org/2001/XMLSchema#string